SANTA ROSA, Calif., April 17, 2014 (GLOBE NEWSWIRE) -- TriVascular Technologies, Inc. (Nasdaq:TRIV), manufacturer of the Ovation Prime™ Abdominal Stent Graft System, today announced the full exercise of the option granted to the underwriters to purchase an additional 975,000 shares of its common stock at a public offering price of $12.00 per share in connection with its previously announced underwritten public offering of 6,500,000 shares of common stock. The company’s shares began trading on The NASDAQ Global Select Market on April 16, 2014 under the ticker symbol “TRIV.”
Help employers find you! Check out all the jobs and post your resume.
